This work not only refines our understanding of how specific Ras effectors promote proliferation (PI3K and MAPK) and survival (RALB) of AML cells, but also provides a biologic basis to guide the rational development of Ras-targeted treatment approaches for AML patients. Here, RALB is linked to acute myeloid leukemia.